Mammalian target of rapamycin inhibition prevents glomerular hypertrophy in a model of renal mass reduction

Transplantation

Volumn 88, Issue 5, 2009, Pages 646-652

  Rovira, Jordi ^a   Arellano, Edgar M ^a,b   Carreras, Joaquim ^c   Campos, Begoña ^d   Vodenik, Barbara ^a   Bañón Maneus, Elisenda ^a   Ramírez Bajo, María José ^a   Moya Rull, Daniel ^a   Solé González, Amanda ^a   Hernández, Astrid ^a   Revuelta, Ignacio ^a   Quintana, Luis F ^a   Howat, William J ^e   Campistol, Josep M ^a   Diekmann, Fritz ^a,f  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF BARCELONA   (Spain)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Nephrectomy; Proteinuria; Rapamycin; Sirolimus

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; CREATININE; IMMUNOSUPPRESSIVE AGENT; PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; CRYOABLATION; DRUG BLOOD LEVEL; KIDNEY FUNCTION TEST; KIDNEY HYPERTROPHY; KIDNEY MASS; KIDNEY TUMOR; MALE; MORPHOLOGY; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; RENAL PROTECTION; SHAM PROCEDURE; THERAPY DELAY; ANIMAL; DISEASE COURSE; DISEASE MODEL; GLOMERULUS; HYPERTROPHY; KIDNEY; KIDNEY DISEASE; METABOLISM; PATHOLOGY; PHYSIOLOGY; WISTAR RAT;

ANIMALS; CREATININE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HYPERTROPHY; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY DISEASES; KIDNEY GLOMERULUS; MALE; PROTEIN KINASES; PROTEINURIA; RATS; RATS, WISTAR; SIROLIMUS;

EID: 70349568501     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181b24463     Document Type: Article

References (45)

1. Brenner BM, Milford L. Nephron, underdosing: A programmed cause of chronic renal allograft failure. Am J Kidney Dis 1993; 21: 66.
2. Hoy WE, Douglas-Denton RN, Hughson MD, et al. A stereological study of glomerular number and volume: Preliminary multiracial study of kidneys at autopsy. Kidney Int Suppl 2003; 83: S31.
3. Nyengaard JR. Number and dimensions of rat glomerular capillaries in normal development and after nephrectomy. Kidney Int 1993; 43: 1049.
4. 4. Alperovich G, Maldonado R, Moreso F, et al. Glomerular enlargement assessed by paired donor and early protocol renal allograft biopsies. Am J Transplant 2004; 4: 650. (Pubitemid 38523589)
5. Li M, Nicholls KM, Becker GJ. Risk factors for late renal allograft dysfunction: Effects of baseline glomerular size. J Nephrol 2002; 15: 620. (Pubitemid 36040561)
6. 6. Li M, Nicholls KM, Becker GJ. Glomerular size and global glomerulosclerosis in normal Caucasians donor kidneys: Effects of aging and gender. J Nephrol 2002; 15: 614. (Pubitemid 36040560)
7. Bhathena DB. Glomerular size and the association of focal glomerulosclerosis in long surviving human renal allografts. J Am Soc Nephrol 1993; 4: 1316.
8. Sehgal SN, Molnar-Kimber K, Okain TD, et al. Rapamycin: A novel immunosuppressive macrolide. Med Res Rev 1994; 14: 1.
9. Groth CG, Bäckman L, Morales JM, et al. Sirolimus (Rapamycin)based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036.
10. Sehgal SN. Sirolimus: Its discovery, biological properties, and mechanism of action. Transplant Proc 2003; 35: 7S.
11. Rovira J, Arellano EM, Burke JT, et al. Effect of mTOR inhibitor on body weight: From an experimental rat model to human transplant patients. Transpl Int 2008; 21: 992.
12. Gutierrez-Dalmau A, Campistol JM. The role of proliferation signal inhibitors in post-transplant malignancies. Nephrol Dial Transplant 2007; 22: i11.
13. van den Akker JM, Wetzels JF, Hoitsma AJ. Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. Kidney Int 2006; 70: 1355.
14. Aliabadi AZ, Pohanka E, Seebacher G, et al. Development of proteinuria after switch, to sirolimus-based immunosuppression in long-term cardiac transplant, patients. Am J Transplant 2008; 8: 854. (Pubitemid 351347752)
15. Dittrich E, Schmaldienst S, Soleiman A, et al. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl hit 2004; 17: 215. (Pubitemid 38758188)
16. Saurina A, Campistol JM, Piera C, et al. Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: Changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant 2006; 21: 488. (Pubitemid 43160007)
17. Izzedine H, Brocheriou I, Frances C. Post-transplantation proteinuria and sirolimus. N Engl J Med 2005; 353: 2088.
18. Straathof-Galema L, Wetzels JFM, Dijkman HBPM, et al. Sirolimusassociated heavy proteinuria in a renal transplant recipient: Evidence for a tubular mechanism. Am J Transplant 2006; 6: 429. (Pubitemid 43382183)
19. Stracke S, Mayer JM, Henne-Bruns D, et al. Abstract 688. Presented at the World Transplant Congress, Boston, MA, July 22-27, 2006.
20. 20. Solà-Villà D, Camacho M, Solà R, et al. IL-1 β induces VEGF, independently of PGE2 induction, mainly through the PI3-K/mTOR pathway in renal mesangial cells. Kidney hit 2006; 70: 1935. (Pubitemid 44863381)
21. 21. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128. (Pubitemid 34155123)
22. Kang DH, Joly AH, Oh SW, et al. Impaired angiogenesis in the remnant kidney model. I. Potential role of vascular endothelial growth, factor and thrombospondin-1. J Am Soc Nephrol 2001; 12: 1434.
23. 23. Kang DH, Hughes J, Mazzali M, et al. Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 2001; 12: 1448. (Pubitemid 32666327)
24. 24. Kelly DJ, Hepper C, Wu LL, et al. Vascular endothelial growth factor expression and glomerular endothelial cell loss in the remnant kidney model. Nephrol Dial Transplant 2003; 18: 1286. (Pubitemid 36826947)
25. 25. Diekmann F, Rovira J, Carreras J, et al. Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass. J Am Soc Nephrol 2007; 18: 2653. (Pubitemid 47531192)
26. 26. Vogelbacher R, Wittmann S, Braun A, et al. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 2007; 84: 1492. (Pubitemid 350294725)
27. Waldherr R, Gretz N. Natural course of the development of histological lesions after 5/6 nephrectomy. Contrib Nephrol 1988; 60: 64.
28. 28. Thomas GL, Yang B, Wagner BE, et al. Cellular apoptosis and proliferation in experimental renal fibrosis. Nephrol Dial Transplant 1998; 13: 2216. (Pubitemid 28416544)
29. 29. Zhang H, Wada J, Kanwar YS, et al. Screening for genes up-regulated in 5/6 nephrectomized mouse kidney. Kidney Int 1999; 56: 549. (Pubitemid 29353153)
30. Woestenburg A, Senncsael J, Bosmans JL, et al. Vasculopathy in the kidney allograft at time of transplantation: Impact on later function of the graft. Transplantation 2008; 85(7 suppl): S10.
31. 31. Escofet X, Osman H, Griffiths DF, et al. The presence of glomerular sclerosis at time zero has a significant impact on function after cadaveric renal transplantation. Transplantation 2003; 75: 344. (Pubitemid 36222960)
32. 32. Ninova D, Covarrubias M, Rea DJ, et al. Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: Differential intragraft expression of transforming growth factor-betal and alpha-smooth muscle actin. Transplantation 2004; 78: 338. (Pubitemid 39095398)
33. 33. Mota A, Arias M, Taskinen EI, et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004; 4: 953. (Pubitemid 38745595)
34. Oberbauer R, Haas M, Regele H, et al. Glomerular permselectivity in proteinuric patients after kidney transplantation. J Clin Invest 1995; 96: 22.
35. Hayslett JP, Kashgarian M, Epstein FH. Functional correlates of compensatory renal hypertrophy. J Clin Invest 1968; 47: 774.
36. 36. Nagai K, Matsubara T, Mima A et al. Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy. Kidney Int 2005; 68: 552. (Pubitemid 43323110)
37. 37. Lloberas N, Cruzado JM, Franquesa M, et al. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 2006; 17: 1395. (Pubitemid 43673420)
38. 38. Radermacher J, Mengel M, Ellis S, et al. The renal arterial resistance index and renal allograft survival. N Engl J Med 2003; 349: 115. (Pubitemid 36818781)
39. Comper WD, Hilliard LM, Nikolic-Paterson DJ, et al. Disease-dependent mechanisms of albuminuria. Am J Physiol Renal Physiol 2008; 295: F1589.
40. Latavemier E, Bruneval P, Mandet C, et al. High sirolimus levels may induce focal segmental glomeruloscleosis de novo. Clin J Am Soc Nephrol 2007; 2: 326.
41. 41. Ruiz JC, Campistol JM, Sanchez-Fructuoso A, et al. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. Nephrol Dial Transplant 2006; 21: 3252. (Pubitemid 44567102)
42. Letavernier E, Pe'raldi MN, Pariente A, et al. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005; 80: 1198.
43. Tumlin JA, Miller D, Near M, et al. A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis. Clin JAm Soc Nephrol 2006; 1: 109.
44. Ruiz JC, Campistol JM, Grinyó JM, et al. Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation 2004;78: 1312.
45. Comper WD, Hilliard LM, Nikolic-Paterson DJ, et al. Diseasedependent mechanisms of albuminuria. Am J Physiol Renal Physiol 2008; 295: F1589.